Archives for February 2009
Winston Pharmaceuticals, Inc. Receives Orphan Drug Designation For Novel Patch To Treat Post-Herpetic Neuralgia
Winston Pharmaceuticals, Inc. (OTC BB: WPHM) today announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead compound, Civamide, a novel TRPV-1 receptor modulator, being developed as a dermal patch for the treatment of post-herpetic neuralgia. Winston recently released results of a Phase I study demonstrating [...]
Non-Profit Gives $800,000 For Melanoma Research In 2009
Today the Melanoma Research Foundation (MRF), the largest independent, national organization devoted to melanoma in the U.S., announced the recipients of five new research grants as part of its Career Development Grant Program and Established Investigator Grant Program.
Original post by Dermatology News From Medical News Today
CHMP Delays European Commission Decision Process To Approve ZEVTERATM
Janssen-Cilag announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on ZEVTERATM (ceftobiprole medocaril) pending completion of a Good Clinical Practice (GCP) inspection. ZEVTERA is in the final stage of approval for the treatment of [...]
Why We Turn Gray
Wash away your gray? Maybe. A team of European scientists have finally solved a mystery that has perplexed humans throughout the ages: why we turn gray. Despite the notion that gray hair is a sign of wisdom, these researchers show in a research report published online in The FASEB Journal (http://www.fasebj.org) that wisdom has nothing [...]
Mouse Model Of A UV Sensitivity Syndrome Illustrates Skin Stem Cell Dysfunction Is Linked To Cancer Pathology
Cell lifespan is limited by telomeres, DNA sequences that cap chromosomes and control the number of times a cell may be copied. A new study reported in Disease Models & Mechanisms (DMM), dmm.biologists.org, describes how telomere dysfunction in skin cells can lead to increased skin cancer risk and pigmentation.
Original post by Dermatology News From [...]
Data Shows Maxorb(R) Extra Ag Capable Of Sustaining Antimicrobial Activity For Up To 21 Days
Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of medical supplies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance supporting the claim that Maxorb(R) Extra Ag is capable of sustained antimicrobial [...]
FDA Advises Public Of Serious Adverse Event With Psoriasis Drug Raptiva
The U.S. Food and Drug Administration issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab). Three of those patients have died. All four patients were treated with the drug for more than three years. None [...]
Advanced Arm Dynamics Develops All-New Silicone Skin Protection For Upper Extremity Amputees
Advanced Arm Dynamics (AAD), the nation’s leading provider of upper extremity prosthetic rehabilitation, introduced an all-new synthetic silicone skin protection for upper extremity amputees. The state of the art skin protection provides amputees with a more comfortable fit along with a significant increase (up to 50 percent) in their range of motion. The [...]
European Medicines Agency Recommends Suspension Of The Marketing Authorisation Of Raptiva (efalizumab)
The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Raptiva (efalizumab), from Serono. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Raptiva no longer outweigh its risks, because of safety concerns, including the occurrence of progressive multifocal leukoencephalopathy (PML) in patients taking [...]
European Medicines Agency Recommends New Contraindication And Warning For Rasilez And Other Aliskiren Medicines
The European Medicines Agency (EMEA) has recommended adding a contra-indication to the Product Information for aliskiren, stating that it must not be used in patients who have experienced angioedema (swelling of the tissues beneath the skin) when taking aliskiren in the past. The Agency also recommended the [...]